Long-term efficacy of ozanimod in relapsing multiple sclerosis in DAYBREAK: An open-label extension of the phase 3 SUNBEAM and RADIANCE trials

Authors
Category Primary study
JournalEuropean Journal of Neurology
Year 2020
This article has no abstract
Epistemonikos ID: f73e762a673709049bf89892d6bb2c05a25546de
First added on: Feb 12, 2025